Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharmaceuticals
Femme et Homme Max 99 ans
Novartis Pharmaceuticals Corp
MAJ Il y a 4 ans
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF9...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals, Japan
MAJ Il y a 4 ans
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to rel...
Pays
Japan
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 4 ans
Topical Diclofenac Gel in Patients With Superficial Inflammation of the Veins
This study will assess the efficacy, safety and tolerability of topically administered diclofenac gel versus placebo with respect to the symptom score (pain, temperature and size of erythe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Limited
MAJ Il y a 4 ans
A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL)
The primary objective of this study is to assess whether treatment with an enteric coated formulation of mycophenolic acid (MPA) permits higher MPA doses to be maintained, than treatment with standard...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 4 ans
RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb study, with 12-month primary endpoint, assessing the efficacy and safety of Lucentis (Ranibizumab) in patients with visual impairment due to diabetic macular oedema
•To evaluate the efficacy of 0.5 mg Lucentis (ranibizumab), as measured by the mean change from baseline in Best Corrected Visual Acuity (BCVA) at 12 months,
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 4 ans
Effect of AQW051 in Patients With Memory Impairment
This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 4 ans
SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension
Assessing the safety and efficacy of SPP100 (Aliskiren) regimen in patients with severe hypertension
Pays
Japan
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 4 ans
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with e...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 4 ans
Study of efficacy and safety of ranibizumab in patients with wet age related macular degeneration that have previously been treated with aflibercept
The primary objective is to evaluate whether treatment with intravitreal ranibizumab is associated with improvement (i.e. reduction at Day 90 from Baseline) in central subfield retinal thickness (CSRT...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Limited
MAJ Il y a 4 ans
Evaluating the benefits of using secukinumab rather than standard treatments as the first systemic treatment in moderate to severe psoriasis
The primary objective is to demonstrate, in systemic treatment-naïve patients with moderate to severe plaque psoriasis, that the cumulative effect of treatment with secukinumab 300 mg over 32 weeks, a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant